Material Safety Data Sheet
(According to 2001/58/EC)
Doc. No. MSDS/ AN-181

Section 1 – Product and Company Information Page 1/3
Product Name: Norfloxacin
Symbol : NX
Disc content : 10mcg
Date Prepared / Revised on: 21-02-2011
Section 2 – Composition, Information on Ingredients
Composition: (per disc)
Norfloxacin NX 10mcg
Material from animal Origin: None
Section 3 – Hazards IdentificationHazard Overview: Inhalation: If inhaled, remove to fresh air. If not breathing, give artificial respiration and immediately seek medical at ention.
Ingestion: Do not induce vomiting unless directed by medical personnel. Do not give anything by mouth to an unconscious person. Skin Contact: Wash thoroughly with soap and water immediately. If irritation persists consult a physician.
Eye Contact:Immediately flush eyes with plenty of water for at least 15 minutes, keeping eyelid open. If irritation persists consult a Suitable Extinguishing Agents: CO2, ABC multipurpose dry chemical or water spray. Fight large fires with water spray or alcohol Protective Equipment: No special measures required.
Section 6 – Accidental Release Measures Wear appropriate protective clothing.
Spil : Sweep up into suitable containers for disposal. Use water to clean up final y.
Section 7 – Handling and Storage Page 2/3
Handling: Avoid inhaling dust. Avoid contact with eyes, skin and clothing.
Storage: Keep container tightly closed. Store as per product specification.
Section 8 – Exposure Control / Personal Protection Wear appropriate NIOSH / MSHA –approved respirator, chemical-resistant gloves, safety goggles, other protective clothing. Section 9 – Physical and Chemical PropertiesForm: Stability: Product is stable if stored as per the conditions specified under storage of Section 7. Product loses its potency /performance above the mentioned storage.
Conditions to Avoid: Heat and Light.
Decomposition Products: No dangerous decomposition products known.
Ef ects of Skin Contact: Causes skin irritation. May be harmful if absorbed through the skin.
Ef ects of Eye Contact: Causes eye irritation.
Ef ects of Ingestion: Harmful if ingested.
Ef ects of Inhalation: Harmful if inhaled. Causes irritation to respiratory system. Additional Toxicological Information:Irritant. Refer to RTECS for Complete Information.
Section 12 – Ecological Information Ecotoxicity: On completion of work al used or unusable preparations of this product and derivatives thereof are to be disposed of by autoclaving and/or by incineration. Dispose of waste in accordance with al applicable Federal, State and local laws.
Section 14 – Transport Information UN No.: Warning Label Text Indication Of Hazard with Symbol: Section 16 – Other Information Page 3/3
To the best of our knowledge the above mentioned information is accurate. However, Microxpress, a Division of Tulip Diagnostics (P) Ltd makes no warranty with respect to its completeness nor assumes any liability resulting from its use. Al material may present unknown hazards than those described above and should be used with caution. Final determination of suitability of any material is the sole responsibility of the user.
Tulip Diagnostics (P) Ltd.
Corporate Office: Gitanjali, Tulip Block,
Dr.Antonio Do Rego Bagh, Bambolim Complex Post Office, Tel: +91 832 2458546/47/48/49/50/51 Fax: +91 832 2458544 Works: Plot No. S-126, Phase II -B,
Tel: + 91 832 2782846 / 47 Fax: + 91 832 2782836

Source: http://www.tulipgroup.com/biogram/msds/Norfloxacin_10.pdf

Microsoft word - acefinal00222.doc

Policies for Reducing the Costs of Cigarette Smoking Harry Clarke and Louise Collis Department of Economics and Finance July 2007 Abstract: Policies for regulating tobacco smoking in Australia are examined. Cigarette management policies need to account for the addictive nature of nicotine, information failures and the existence of externalities and internalities. The external

S4096 bd journal 1.2 sb7

S4433 CABD 2.2 PJ7 5/8/03 5:15 pm Page 49 PJonas PJ's G4 hard disk:Desktop Folder: K E Y R E V I E W Clinical Applications of Levothyroxine in Refractory Mood Disorders M Bauer,1,2* M Adli,1 T Bschor,3 A Heinz,1 N Rasgon,4 M Frye,2 H Grunze,5 R Kupka,6 and PC Whybrow2 1Department of Psychiatry and Psychotherapy, Humboldt University at Berlin, Charité University Hospital, Schuma

Copyright © 2018 Medical Abstracts